Monday, March 16, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Neither side should expect dramatic shifts — even if Supremes scrap Roe v. Wade

Texas Right to Life says SB8, the state law that prohibits abortion after fetal cardiac activity can be detected, has “saved at least 100 lives PER DAY” since it took effect on Sept. 1. Another calculation suggests the number “could be as high as 132.”

One reason for the uncertainty is that Texas women who have crossed SB8’s legal threshold, which typically happens around six weeks into a pregnancy, can still obtain abortions in other states with less restrictive policies. In that respect, recent experience in Texas offers a preview of what will happen if the Supreme Court decides, contrary to what it has been saying for nearly half a century, that the Constitution does not protect a woman’s right to abortion after all.

A case the justices will hear next month, involving Mississippi’s ban on elective abortions performed after 15 weeks, presents an opportunity to revisit those precedents. But if the court repudiates them, the consequences will be much less dramatic than anti-abortion activists hope and abortion advocates fear.

Source: New York Post

https://nypost.com/2021/10/21/neither-side-should-expect-dramatic-shifts-even-if-supremes-scrap-roe-v-wade/

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

2027 Medicare Advantage & Part D Advance Notice

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!